Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...

As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last ...

Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

IPOs at three biotechs last week tempted insiders to make huge share purchases. This spilled over into buying at a couple of ...

Scott Rapoport earned his PhD in marine biology from Scripps Institution of Oceanography at UC San Diego in 2003. Drawn to ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

The vaccine market might be a crowded one, but London-based Vicebio aspires to cement its own place within it. The startup ...

Moleculin Biotech shares were up 12% to $2.65 after the company said it saw positive in vivo efficacy data of Annamycin in lung metastatic models of sarcoma. The stock is approaching its 52-week low ...

The new firm is raising a $150 million fund to back startups around science emerging outside Boston and San Francisco.

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...